文献速递心力衰竭与心肌病

基线肾功能不全对COAPT试验中重度二尖瓣反流心衰患者心脏结局及终末期肾病的影响

Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.
PubMed 文献 · Eur Heart J · 2022-01-01

COAPT试验随机分配614例心衰合并重度二尖瓣反流患者至MitraClip+指南导向药物治疗(GDMT)或单独GDMT,按基线eGFR分层为无、中度、重度肾功能不全。基线肾功能不全占77.0%,肾功能越差,2年死亡或心衰住院风险越高;MitraClip降低新发终末期肾病和需要肾脏替代治疗的风险。

要点

  • 基线肾功能不全是心衰合并重度二尖瓣反流患者的常见合并症,占77.0%。
  • 肾功能越差,2年死亡或心衰住院风险越高。
  • MitraClip可降低新发终末期肾病和需要肾脏替代治疗的风险。

核心结论

  • 基线肾功能不全在COAPT试验的重度二尖瓣反流心衰患者中常见,并强烈预测2年死亡和心衰住院。
  • MitraClip治疗降低了新发终末期肾病和需要肾脏替代治疗的风险,有助于改善经导管二尖瓣修复后的预后。

研究设计与样本

  • COAPT试验随机分配614例心衰合并重度二尖瓣反流患者至MitraClip+GDMT或单独GDMT。
  • 按基线eGFR(mL/min/1.73 m2)分层为无(≥60)、中度(30-60)、重度(<30)肾功能不全三个亚组。
  • 终末期肾病定义为eGFR <15 mL/min/1.73 m2或需要肾脏替代治疗。
  • 评估2年全因死亡或心衰住院、新发终末期肾病和肾脏替代治疗率。

主要发现

  • 基线肾功能不全占77.0%,其中重度23.8%,终末期肾病6.0%,肾脏替代治疗5.2%。
  • 肾功能越差,2年死亡或心衰住院风险越高:无45.3%,中度53.9%,重度69.2%(P < 0.0001)。
  • MitraClip vs 单独GDMT改善结局与肾功能分层无关(Pinteraction = 0.62)。
  • MitraClip降低新发终末期肾病(2.9% vs 8.1%,HR 0.34,95%CI 0.15-0.76,P = 0.008)。
  • MitraClip降低需要新肾脏替代治疗(2.5% vs 7.4%,HR 0.33,95%CI 0.14-0.78,P = 0.011)。

临床怎么用

  • 对心衰合并重度二尖瓣反流患者应评估基线肾功能,以识别高危人群。
  • MitraClip治疗可考虑用于减少新发终末期肾病和肾脏替代治疗需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Baseline renal dysfunction (RD) adversely impacts outcomes among patients with heart failure (HF) and severe secondary mitral regurgitation (MR). Heart failure and MR, in turn, accelerate progression to end-stage renal disease (ESRD), worsening prognosis. We sought to determine the impact of RD in HF patients with severe MR and the impact of transcatheter mitral valve repair (TMVr) on new-onset ESRD and the need for renal replacement therapy (RRT). METHODS AND RESULTS: The COAPT trial randomized 614 patients with HF and severe MR to MitraClip plus guideline-directed medical therapy (GDMT) vs. GDMT alone. Patients were stratified into three RD subgroups based on baseline estimated glomerular filtration rate (eGFR, mL/min/1.73 m2): none (≥60), moderate (30-60), and severe (<30). End-stage renal disease was defined as eGFR <15 mL/min/1.73 m2 or RRT. The 2-year rates of all-cause death or HF hospitalization (HFH), new-onset ESRD, and RRT according to RD and treatment were assessed. Baseline RD was present in 77.0% of patients, including 23.8% severe RD, 6.0% ESRD, and 5.2% RRT. Worse RD was associated with greater 2-year risk of death or HFH (none 45.3%; moderate 53.9%; severe 69.2%; P < 0.0001). MitraClip vs. GDMT alone improved outcomes regardless of RD (Pinteraction = 0.62) and reduced new-onset ESRD [2.9 vs. 8.1%, hazard ratio (HR) 0.34, 95% confidence interval (CI) 0.15-0.76, P = 0.008] and the need for new RRT (2.5 vs. 7.4%, HR 0.33, 95% CI 0.14-0.78, P = 0.011). CONCLUSION: Baseline RD was common in the HF patients with severe MR enrolled in COAPT and strongly predicted 2-year death and HFH. MitraClip treatment reduced new-onset ESRD and the need for RRT, contributing to the improved prognosis after TMVr.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Beohar, Ailawadi, Kotinkaduwa, et al. Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial. Eur Heart J. 2022. PMID: 35134897. doi:10.1093/eurheartj/ehac026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。